Amylyx Pharmaceuticals Files 2024 10-K
Ticker: AMLX · Form: 10-K · Filed: Mar 4, 2025 · CIK: 1658551
Sentiment: neutral
Topics: 10-K, pharmaceuticals, annual-report
TL;DR
Amylyx dropped its 2024 10-K. Full financials and biz update.
AI Summary
Amylyx Pharmaceuticals, Inc. filed its 2024 10-K on March 4, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in Cambridge, MA, operates in the pharmaceutical preparations sector. Key financial data and operational details for the fiscal year 2024 are presented in this filing.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Amylyx Pharmaceuticals' financial performance, operational status, and strategic direction for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Amylyx faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2834 — SIC Code (Indicates the company operates in Pharmaceutical Preparations)
Key Players & Entities
- Amylyx Pharmaceuticals, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-04 (date) — Filing date
- Cambridge, MA (location) — Company headquarters
FAQ
What were Amylyx Pharmaceuticals' total revenues for the fiscal year ending December 31, 2024?
The provided text does not contain specific revenue figures for the fiscal year ending December 31, 2024.
What is the primary business address of Amylyx Pharmaceuticals?
The primary business address is 43 THORNDIKE STREET, CAMBRIDGE, MA 02141.
When was the 10-K filing for the fiscal year 2024 submitted to the SEC?
The 10-K filing was submitted on March 4, 2025.
What is the Standard Industrial Classification (SIC) code for Amylyx Pharmaceuticals?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Does the filing mention any specific product names or drug development programs?
The filing mentions 'OtherProgramsMember' and 'TwoThousandAndTwentyThreeInducementPlanMember' but does not detail specific drug names or their development status.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 4, 2025 regarding Amylyx Pharmaceuticals, Inc. (AMLX).